Testis cancer: Surgery is back again
Thematic Session 09

Location: Green Area, Room 20
Chairs: P. Albers, Düsseldorf (DE)  
        J.L. Boormans, Rotterdam (NL)

Aims and objectives of this session
This session will provide you with up-to-date knowledge on the pathogenesis of germ cell tumors followed by a debate on a still controversial issue of primary RPLND for staging and treatment in patients with high risk clinical stage I non-seminoma. In a state-of-the-art latest data on one of the most dangerous histological transformations will be presented: Somatic malignancies in teratoma. The session will conclude with evidence-based recommendations for follow-up and two of the best abstracts on epidemiology and quality of care in testicular cancer.

10:30 - 10:42  The cause of everything: The testicular dysgenesis syndrome  
P. Albers, Düsseldorf (DE)

10:42 - 10:45  Discussion

10:45 - 11:15  Debate  Surgery for non-seminoma clinical stage I "high risk"

10:45 - 10:57  Pro surgery  
S. Daneshmand, Los Angeles (US)

10:57 - 11:09  Con surgery  
D.. Nicol, London (GB)

11:09 - 11:15  Discussion

11:15 - 11:27  Surgical management for Somatic Malignant-transformed teratoma (SM)  
N.W. Clarke, Manchester (GB)

11:27 - 11:30  Discussion

11:30 - 11:42  Challenging the guidelines  Risk-based follow-up schedules for testis cancer  
R. Cathomas, Chur (CH)

11:42 - 11:45  Discussion

11:45 - 11:59  Associated abstract presentations
1239  Non-guideline concordant treatment of testicular cancer patients is associated with a significantly reduced event-free survival

By: Paffenholz P., Osterholt T., Nestler T., Pfister D., Heidenreich A.
University Hospital Cologne, Dept. of Urology, Cologne, Germany

1240  Contemporary assessment of survival rates in stage I testicular seminoma: A population-based comparison between surveillance and active treatment after initial orchiectomy

By: Mistretta F.A. 1, Mazzone E. 1, Palumbo C. 1, Knipper S. 1, Tian Z. 1, Nazzani S. 1, Lattouf J-B. 2, Musi G. 3, Perrotte P. 2, Montanari E. 4, Shariat S.F. 5, Montorsi F. 6, Saad F. 7, De Cobelli O. 3, Karakiewicz P.I. 1

1University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 2University of Montreal Health Center, Dept. of Urology, Montreal, Canada, 3European Institute of Oncology, Dept. of Urology, Milan, Italy, 4IRCCS Fondazione Ca’a Granda-Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, 5Medical University of Vienna, Dept. of Urology, Vienna, Austria, 6IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Dept. of Oncology, Unit of Urology, URI, Milan, Italy, 7University of Montreal Hospital Center, Dept. of Urology, Montreal, Canada